Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome
Sign Up to like & getrecommendations! Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34722
Abstract: Patients with cytopenic myelofibrosis (MF) have more limited therapeutic options and poorer prognoses compared with patients with the myeloproliferative phenotype. read more here.
Keywords: myelofibrosis response; response toxicity; ruxolitinib cytopenic; cytopenic myelofibrosis ... See more keywords
5-Fluorouracil Response Prediction and Blood Level-guided Therapy in Oncology: Existing Evidence Fundamentally Supports Instigation.
Sign Up to like & getrecommendations! Published in 2020 at "Therapeutic Drug Monitoring"
DOI: 10.1097/ftd.0000000000000788
Abstract: 5-Fluorouracil (5-FU) response prediction and therapeutic drug monitoring (TDM) are required to minimize toxicity while preserving efficacy. Conventional 5-FU dose normalization uses body surface area (BSA). It is characterized by up to 100-fold inter-individual variability… read more here.
Keywords: response; toxicity; prediction; response toxicity ... See more keywords
Correlation of response to stereotactic radiotherapy and immunotherapy with toxicity and predictions by differences in Treg population.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e14039
Abstract: e14039 Background: Combining stereotactic ablative radiotherapy (SABR) and anti-PD1 therapy may result in synergism but the response and toxicity rates has not been established. Biomarkers to predict clinical outcomes in this setting could improve patient… read more here.
Keywords: response; immunotherapy; toxicity; treg population ... See more keywords
Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise
Sign Up to like & getrecommendations! Published in 2022 at "Diagnostics"
DOI: 10.3390/diagnostics12010124
Abstract: Immune checkpoint inhibitors are monoclonal antibodies that are used to treat over one in three cancer patients. While they have changed the natural history of disease, prolonging life and preserving quality of life, they are… read more here.
Keywords: cancer; response toxicity; immune checkpoint; checkpoint inhibitors ... See more keywords